Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.30%
As of Wednesday, September 30, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.49%
As of Tuesday, September 15, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Michael Rose
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.60%
As of Tuesday, August 25, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 5.60%, which has investors questioning if this is right time to sell.Michael Rose
Is Enanta Pharmaceuticals, Inc. (ENTA) Overvalued?
We dive into why Enanta Pharmaceuticals, Inc. (ENTA) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Michael Rose
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 6.23%
As of Tuesday, August 11, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 6.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $383.9 | $257.1 | 35% |
|
| Shares Out (Mil) | 29.1 | 54.0 | 36% |
|
| Institutional Ownership | 94.4% | 93.2% | 65% |
|
| Float (Mil) | 22.5 | 41.3 | 31% |
|
| Beta | 0.93 | 0.95 | 56% |
|
| Avg Daily Volume (000s) | 282 | 728 | 47% |
|
| Price Change (52-week) |
(13.1%) | 50.6% | 41% |
|
| Growth | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (11.8%) | 12.8% | 4% |
|
| Net Income (5yr) | (17.7%) | (10.1%) | 22% |
|
| EPS (5yr) | (16.2%) | 15.7% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.770) | ($2.293) | ($2.374) | |
| Month Ago EPS | ($0.770) | ($2.293) | ($2.374) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.673) | ($1.962) | ($1.975) | |
| Year/Year Chg | 14.9% | (40.3%) | (40.8%) | |
| Financials | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $37 | 22% |
|
| Net Income (TTM) (Mil) | ($63) | ($44) | 14% |
|
| EPS (TTM) | ($2.336) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($33) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $141 | $4 | 47% |
|
| Enterprise Value (Q1) (Mil) | $362 | $173 | 31% |
|
| Valuation | ENTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.80 | 2.52 | 73% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.2% | 96% |
|
| Net Margin | (96.9%) | (73.7%) | 8% |
|
| ROA | (21.2%) | (47.7%) | 20% |
|
| ROE | (70.1%) | (54.9%) | 12% |
|
| Liabilities to Assets | 66.0% | 29.0% | 61% |
|
| F-Score | 4 | 3 | 33% |
|
Enanta Pharmaceuticals, Inc. did not pass any screens on 9/30/2026.
